---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-109353"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:47:24.151267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa posts Q4 net loss $46.1M; cash runway into 2029; positive Phase 1 data for NEK7 degrader MRT-8102

## Summary
- Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.
- Cash, equivalents, securities $382.1M at Dec 31, 2025; $345M Jan 2026 offering extends runway into 2029.
- Interim Phase 1 data for NEK7 degrader MRT-8102: 85% CRP reduction in elevated CVD-risk subjects; unblinded safety shows no SAEs.
- Plans to initiate multiple Phase 2 studies of MRT-8102 in H2 2026 (ASCVD, gout, hidradenitis suppurativa).
- MRT-2359 in mCRPC with AR mutations: 100% PSA response rate; Phase 2 with apalutamide planned Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-109353
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/0001193125-26-109353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-109353
- JSON: https://secwatch.observer/filing/0001193125-26-109353.json
- Plain text: https://secwatch.observer/filing/0001193125-26-109353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.